Sees Q4 adjusted EBITDA $14M-$17M.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HIMS:
- Hims & Hers (NYSE:HIMS) Soars on Healthy Q3 Performance
- Hims and Hers Health options imply 14.4% move in share price post-earnings
- HIMS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Hims & Hers appoints Khobi Brooklyn as CCO
- HealthEquity price target raised to $110, named a ‘Best Idea’ at Guggenheim